Human Longevity, Inc. (HLI), a San Diego, CA-based genomics-based, technology-driven company, raised in excess of $220m in Series B funding.
Backers included Illumina, Celgene, GE Ventures, and Series A investors, which represent a diverse geographic pool of investors based in the United Kingdom, Malaysia, Mexico, Australia, Kuwait, Hong Kong, and China, in addition to the US.
The company, which previously raised $80m in a Series A round closed in Summer 2014, is using the proceeds to fund the growth and expansion of its line of products, including Health Nucleus, its genomic-enhanced, research-based health center; ongoing development of the HLI Knowledgebase which currently has more than 20,000 complete genomes coupled with phenotype data; the Comprehensive Cancer Program and other sequencing programs.
Led by J. Craig Venter, Ph.D., Co-founder and CEO, HLI is a genomics-based, technology-driven company creating a large database of whole genome, phenotype and clinical data. The company is developing and applying large scale computing and machine learning to make novel discoveries in the field of medicine. HLI’s business also includes the HLI Health Nucleus™, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver a complete picture of individual health.